Sawasaki K.,Hamamatsu Medical Center |
Sato T.,Hamamatsu Medical Center |
Takayama Y.,Hamamatsu Medical Center |
Yokota S.,Hamamatsu Medical Center |
And 5 more authors.
Journal of Arrhythmia | Year: 2012
Introduction: Surgical procedures for pacemaker implantation vary among facilities. The extrathoracic venous puncture method has been utilized for lead insertion, although patients' body movements can displace the targeted vein from the area into which a contrast agent has been injected for imaging. Failed punctures cause edema around the puncture site, spasm, or venous collapse due to bleeding, which may render another puncture impractical. To overcome these problems, we report a new technique for the extrathoracic puncture method. Methods and results: From April 2007 through March 2011, we performed 35 new dual chamber pacemaker implantation procedures. This study compared a conventional puncture group (from April 2007 through March 2009; Group A) with a catheter-guided puncture group (from April 2009 through March 2011; Group B). We analyzed procedure time and procedure-related complications in each group. The procedure time was 138.6 ± 41.8 min in the conventional puncture group (Group A) and 109.8 ± 23.2 in the catheter-guided puncture group (Group B). There was a significant reduction in the procedure time in the catheter-guided puncture group (Group B) compared with the conventional puncture group (Group A; p=0.016). No patients in either group had pneumothorax, hematoma, or any other complications. Conclusion: Our puncture method involving catheter insertion appears to be safe and effective. © 2012 Japanese Heart Rhythm Society.
Shimada K.,Nagoya University |
Murase T.,Nishio Municipal Hospital |
Matsue K.,Kameda General Hospital |
Ichikawa N.,Red Cross |
And 14 more authors.
Cancer Science | Year: 2010
Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity with a high incidence of central nervous system (CNS) involvement at diagnosis. To evaluate CNS involvement, particularly recurrence including progression on therapy and relapse of IVLBCL, we retrospectively analyzed 109 patients with IVLBCL receiving chemotherapies with or without rituximab. In 82 patients (75%) without CNS involvement at initial diagnosis, risk of CNS recurrence at 3 years was 25% with a median follow-up in survivors of 39 months (range, 2-158 months). In 27 patients (25%) with CNS involvement at initial diagnosis, risk of CNS recurrence at 1 year was 25% with a median follow-up in survivors of 18 months (range, 10-77 months). Duration from diagnosis to CNS recurrence tended to be short in patients with CNS involvement at diagnosis. No significant difference in risk of CNS recurrence was found between patients receiving chemotherapies with or without rituximab. On multivariate analysis skin involvement at initial diagnosis was identified as a predictive factor for CNS recurrence in patients without CNS involvement at diagnosis (hazard ratio, 5.27; 95% confidence interval, 1.59-17.4; P = 0.007). Survival rate after CNS recurrence at 2 years was 12% in patients without CNS involvement at diagnosis. Central nervous system recurrence is a serious complication in IVLBCL patients and optimal strategies for CNS involvement should be established to obtain further improvements to clinical outcomes in the rituximab era. (Cancer Sci 2010). © 2010 Japanese Cancer Association.
Nakanishi K.,Komaki City Hospital |
Kobayashi D.,Nagoya University |
Mochizuki Y.,Komaki City Hospital |
Ishigure K.,Konan Kosei Hospital |
And 7 more authors.
International Journal of Clinical Oncology | Year: 2016
Background: The aim of this study was to explore whether a combination of S-1 and paclitaxel offers any benefit over paclitaxel alone to patients pretreated by S-1. Methods: Gastric cancer patients who developed progression during S-1-based first-line chemotherapy or had recurrence during postoperative adjuvant chemotherapy by S-1 were randomly assigned to receive second-line treatment either by weekly administration of paclitaxel at 80 mg/m2 three times every 4 weeks or daily oral S-1 (80 mg/m2) for 2 weeks plus paclitaxel (50 mg/m2) given on days 1 and 8, every 3 weeks (S-1 plus paclitaxel). The primary endpoint was progression-free survival (PFS) at 4 months after the initiation of treatment. Results: A total of 78 patients were eligible for efficacy analyses—40 were assigned to the paclitaxel group and 38 to the S-1 plus paclitaxel group. PFS at 4 months was similar between the groups (50 % for paclitaxel vs 55 % for S-1 plus paclitaxel, P = 0.641). There were no differences between the groups either in progression-free survival (4.6 vs 4.6 months, respectively, P = 0.526), overall survival (10.0 vs 10.0 months, respectively, P = 0.464), or overall response rate (27 vs 22 %, respectively, P = 0.767). The incidences of grade 3 or 4 hematological and non-hematological toxicities were also equivalent between the two groups (25 vs 26 % and 24 vs 26 %, respectively). Conclusions: No benefit of S-1 administration beyond progression was shown when paclitaxel was selected as the key drug for second-line chemotherapy. © 2015, Japan Society of Clinical Oncology.
PubMed | Komaki City Hospital, Aichi Cancer Center Hospital, Konan Kosei Hospital, Nishio Municipal Hospital and 5 more.
Type: Clinical Trial, Phase II | Journal: International journal of clinical oncology | Year: 2016
The aim of this study was to explore whether a combination of S-1 and paclitaxel offers any benefit over paclitaxel alone to patients pretreated by S-1.Gastric cancer patients who developed progression during S-1-based first-line chemotherapy or had recurrence during postoperative adjuvant chemotherapy by S-1 were randomly assigned to receive second-line treatment either by weekly administration of paclitaxel at 80mg/m(2) three times every 4weeks or daily oral S-1 (80mg/m(2)) for 2weeks plus paclitaxel (50mg/m(2)) given on days 1 and 8, every 3weeks (S-1 plus paclitaxel). The primary endpoint was progression-free survival (PFS) at 4months after the initiation of treatment.A total of 78 patients were eligible for efficacy analyses-40 were assigned to the paclitaxel group and 38 to the S-1 plus paclitaxel group. PFS at 4months was similar between the groups (50% for paclitaxel vs 55% for S-1 plus paclitaxel, P=0.641). There were no differences between the groups either in progression-free survival (4.6 vs 4.6months, respectively, P=0.526), overall survival (10.0 vs 10.0months, respectively, P=0.464), or overall response rate (27 vs 22%, respectively, P=0.767). The incidences of grade 3 or 4 hematological and non-hematological toxicities were also equivalent between the two groups (25 vs 26% and 24 vs 26%, respectively).No benefit of S-1 administration beyond progression was shown when paclitaxel was selected as the key drug for second-line chemotherapy.
Nakashima M.,Nagoya University |
Sakai T.,Nagoya University |
Hiraiwa H.,Nagoya University |
Hamada T.,Nagoya University |
And 10 more authors.
Biochemical and Biophysical Research Communications | Year: 2012
S100A12 is a member of the S100 protein family, which are intracellular calcium-binding proteins. Although there are many reports on the involvement of S100A12 in inflammatory diseases, its presence in osteoarthritic cartilage has not been reported. The purpose of this study was to investigate the expression of S100A12 in human articular cartilage in osteoarthritis (OA) and to evaluate the role of S100A12 in human OA chondrocytes. We analyzed S100A12 expression by immunohistochemical staining of cartilage samples obtained from OA and non-OA patients. In addition, chondrocytes were isolated from knee cartilage of OA patients and treated with recombinant human S100A12. Real-time RT-PCR was performed to analyze mRNA expression. Protein production of matrix metalloproteinase 13 (MMP-13) and vascular endothelial growth factor (VEGF) in the culture medium were measured by ELISA. Immunohistochemical analyses revealed that S100A12 expression was markedly increased in OA cartilages. Protein production and mRNA expression of MMP-13 and VEGF in cultured OA chondrocytes were significantly increased by treatment with exogenous S100A12. These increases in mRNA expression and protein production were suppressed by administration of soluble receptor for advanced glycation end products (RAGE). Both p38 mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) inhibitors also suppressed the increases in mRNA expression and protein production of MMP-13 and VEGF. We demonstrated marked up-regulation of S100A12 expression in human OA cartilages. Exogenous S100A12 increased the production of MMP-13 and VEGF in human OA chondrocytes. Our data indicate the possible involvement of S100A12 in the development of OA by up-regulating MMP-13 and VEGF via p38 MAPK and NF-κB pathways. © 2012 Elsevier Inc.
Fukui M.,Nagoya University |
Takai Y.,Nagoya University |
Tanabe Y.,Social Insurance Chukyo Hospital |
Ukai K.,Nagoya University |
And 2 more authors.
Journal of AAPOS | Year: 2011
Strabismus surgery can lead to successful eye alignment but may cause scarring and distortion of conjunctiva and adjacent structures in some cases. We report two patients who developed epiphora when the lacrimal caruncles became distorted after strabismus surgery. Both cases followed successful medial rectus muscle resections for exotropia. A simple excision of the caruncles improved the epiphora and produced a satisfactory appearance. Copyright © 2011 Published by Elsevier Inc. on behalf of American Association for Pediatric Ophthalmology and Strabismus.
Horio J.,Nagoya University |
Takai Y.,Nagoya University |
Iwata E.,Nishio Municipal Hospital |
Iwase C.,Nagoya University |
And 3 more authors.
Japanese Journal of Clinical Ophthalmology | Year: 2016
Purpose: To reveal the influence of anticoagulants/antiplatelets on the strabismus surgery. Subjects and Methods: Ten patients in Nagoya University Hospital, seven male and three female, were taking anticoagulants/antiplatelets and had undergone rectus muscle recession/resection procedures under local anesthesia during the period of August 2011-March 2015. The mean age of participants were 65.1-10.4 years old. Operation time, anti-thrombotic medication, international normalized ratioprothrombin time (PT-INR), perioperative hemorrhagic complication were extracted from clinical records. Results: Before operation, five patients withdrawn antiplatelets, one patient who was at higher risk of infarction used heparin sodium as a replacement for anticoagulants, another patient used dalteparin sodium to replace antiplatelet, two patients taking antiplatelets and one patient taking anticoagulant did not withdraw. During the perioperative period, no remarkable ocular and general complications were found even if the medications were withdrawn, except for one patient who was using ethyl icosapentate for hypertension, who visited the emergency room after surgery because of severe subconjunctival hemorrhage. Mild hemorrhage was observed in all patients. Mean PT-INR one week before operation was 1.6 ± 0.2 (n = 2) for who anticoagulants group and 0.98 ± 0.07 (n = 8) for antiplatelets group. Conclusions: Any severe complications were not observed.
Tanaka K.,Nagoya University |
Adachi Y.,Nagoya University |
Adachi Y.,Nishio Municipal Hospital |
Suzuki S.,Nagoya University |
And 2 more authors.
Japanese Journal of Anesthesiology | Year: 2012
We encountered three patients who showed ECG changes, suggesting cardiac conduction abnormality, immediately after the induction of general anesthesia with remifentanil and thiamylal. The first patient was a 42-year-old man (172 cm and 75 kg). The second patient was a 75-year-old woman (153 cm and 62 kg) and the last patient was 16-year-old woman (166 cm and 46 kg). Remarkable past history was not noted and pre-anesthetic evaluations including 12 lead electrocardiogram demonstrated no abnormality in all patients. Immediately after the induction of anesthesia, atrioventricular dissociation, sinus arrest and atrioventricular junctional rhythm were diagnosed by monitoring elec trocardiogram, respectively. The conduction abnormalities were not followed by severe bradycardia and hypotension, and observed without drug administration. In the first and second patient, sinus rhythm returned within 15 to 20 min after the induction. The junctional rhythm in the third patient continued during the operation ; however, the recovery to sinus rhythm was observed at the end of operation lasting about 1 hr. No severe adverse clinical complication was found ; however, careful monitoring might be required to prevent circulatory depression with combination of remifentanil and thiamylal.
A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab
Asano T.,Nishio Municipal Hospital |
Negita M.,Nishio Municipal Hospital |
Uemura T.,Nishio Municipal Hospital |
Takagi D.,Nishio Municipal Hospital |
And 2 more authors.
Japanese Journal of Cancer and Chemotherapy | Year: 2012
A 63-year-old woman with chief complaints of abdominal distention and vomiting was brought to our hospital in May, 2010. Her radiological examination revealed that she was suffering from perforative peritonitis. The patient underwent emergency open laparotomy. Perioperatively, we made a diagnosis of unresectable transverse colon cancer accompanied with tough peritoneal dissemination, and therefore performed intraperitoneal irrigation drainage, transverse loop colostomy and biopsy of omental dissemination. A pathological examination of omental dissemination demonstrated mucinous adenocarcinoma with the wild-type Kras gene, and the cytology of ascites was negative. FOLFOX4 combined with panitumumab therapy was initiated 1 month after the operation. Seventeen courses of this chemotherapy regimen were performed, although adverse events including grade 3 neutropenia and grade 2 skin symptoms were noted. Consequently, serum CEA levels decreased to 5.5 ng/mL, although the size of the primary lesion of transverse colon cancer was unchanged on abdominal computed tomography (CT). Chemotherapy has been continued without marked side effects, although 1 year has passed since we started medical treatment for this difficult case. We found that a multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab is useful for patients with highly advanced mucinous adenocarcinoma of the colon that develops into peritoneal dissemination.
Okumura N.,Nagoya University |
Fujii T.,Nagoya University |
Ishikawa T.,Nishio Municipal Hospital |
Yamada S.,Nagoya University |
And 3 more authors.
Japanese Journal of Gastroenterological Surgery | Year: 2013
We report a case of a 66-year-old man who was given a diagnosis of pancreatic head cancer with involvement of the superior mesenteric vein and nerve plexus around the superior mesenteric artery. We started combined chemotherapy of S-1 (tegafur, gimeracil, oteracil potassium) and gemcitabine as neoadjuvant chemotherapy. The patient was seen at the hospital because of severe anemia after one course, and upper gastrointestinal endoscopy showed duodenal bleeding. Chemotherapy was stopped, and curative resection was performed. Histopathological examination revealed the penetration of the necrotic tumor at the bleeding site, possibly resulting from chemotherapy. To the best of our knowledge, this is the first report of a resected case of pancreatic cancer with perforation or penetration to the gastrointestinal tract during neoadjuvant chemotherapy or chemoradiotherapy. An oncologic emergency should be taken into consideration when neoadjuvant treatment is applied to the patient with pancreatic cancer. © 2013 The Japanese Society of Gastroenterological Surgery.